Medicines and Medical Devices Bill

AMENDMENTS

TO BE MOVED

ON REPORT

After Clause 6

LORD FIELD OF BIRKENHEAD
BARONESS MEACHER

Insert the following new Clause—

"Entitlement of a doctor to prescribe medicinal cannabis products

The appropriate authority must by regulations make provision to—

(a) grant authorisation to place on the market of the United Kingdom high quality, standardised medicinal cannabis products for prescription by a doctor (including, for the avoidance of doubt, by a general medical practitioner),

(b) permit doctors to prescribe medicinal cannabis products, and any device or article that is required in the administration of such products, and

(c) require the relevant regulatory and advisory bodies to obtain and evaluate relevant scientific and medical literature and data, including on long-term patients' experience in connection with cannabis for medicinal use (as well as the potential for such use) with particular reference to—

(i) the efficacy and therapeutic value of medicinal cannabis products,

(ii) matters pertaining to the safety of medicinal cannabis products, and

(iii) the medical conditions (indications) in respect of which medicinal cannabis products may be administered and used."

Clause 14

BARONESS FINLAY OF LLANDAFF

Page 9, line 40, leave out "or" and insert "and"

Member's explanatory statement
This amendment is to ensure early access for NHS patients to medical devices and would allow monitoring of safety and efficacy in real time use.

After Clause 40

LORD HUNT OF KINGS HEATH

Insert the following new Clause—

"Availability of medicines and medical devices for human use on the National Health Service

(1) The National Institute for Health and Care Excellence must have regard to the need—

(a) to address the implications of health inequalities when assessing the cost effectiveness of medicines and medical devices,

(b) to support early patient access to effective new medicines and medical devices, including by accepting a greater degree of uncertainty and risk in recommending their use,

(c) to ensure patients with rare diseases have access to medicines and medical devices that they need, and

(d) to support the use of curative therapies involving medicines and medical devices.

(2) The Secretary of State must lay a report and impact assessment before both Houses of Parliament setting out how the National Institute for Health and Care Excellence has implemented its duty under subsection (1), in particular in its manual on process and methods for developing NICE guidelines."

Member's explanatory statement

This new Clause would require the National Institute for Health and Care Excellence to ensure that its recommendations support the NHS in the ways described in subsection (1).

Medicines and Medical Devices Bill

AMENDMENTS

TO BE MOVED

ON REPORT

---

30 November 2020
